Shandong Sanyuan Biotechnology Co., Ltd. (301206.SZ) has released its Q3 2025 report, indicating that the company's revenue for the first three quarters amounted to 476 million yuan, a year-on-year decrease of 7.54%. The net profit attributable to shareholders was 67.3987 million yuan, a decline of 16.80% compared to the previous year. After excluding non-recurring gains and losses, the net profit attributable to shareholders was 57.1343 million yuan, representing a year-on-year decrease of 28.11%. The basic earnings per share were 0.34 yuan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments